Description of Collaborative Activity: |
The ACCORD study was primarily composed of three clinical trials that tested treatment approaches to determine the best ways to decrease the high rate of major CVD events – heart attack, stroke, or death from CVD – among people with type 2 diabetes who are at especially high risk of having a CVD event, like a heart attack or stroke. ACCORDION (the ACCORD Follow-up Study) is a prospective, observational follow-up study of approximately 8000 participants who were treated and followed in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. It is designed to further elucidate and clarify the long-term effects of the ACCORD treatment strategy and provide additional data on the long-term relationships among various cardiovascular and diabetic risk factors. ACCORD participants had type 2 diabetes and were at high risk for a CVD event. Those who agree to participate in ACCORDION will continue to be followed through clinic and phone visits for an average of 3.5 years in the period 2011 through 2014. Participants will be seen in 76 clinics across the United States and Canada. The CDC is contributing intellectually and financially to the Health Related Quality of Life and Cost Effectiveness substudies of the trial. |
